# Samuel W Brady

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11467102/publications.pdf

Version: 2024-02-01

| 23 | 1,546 | 430874 | 677142 |
|---|---|---|---|
| papers | citations | 18 h-index | 22 g-index |

| 24 | 24 | 24 | 3215 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Therapeutic and prognostic insights from the analysis of cancer mutational signatures. Trends in Genetics, 2022, 38, 194-208. | 6.7 | 39 |
| 2 | A `one-two punch' therapy strategy to target chemoresistance in estrogen receptor positive breast cancer. Translational Oncology, 2021, 14, 100946. | 3.7 | 8 |
| 3 | Exploration of Coding and Non-coding Variants in Cancer Using GenomePaint. Cancer Cell, 2021, 39, 83-95.e4. | 16.8 | 18 |
| 4 | The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms. Nature Communications, 2021, 12, 985. | 12.8 | 31 |
| 5 | Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Diseaseâ€“Directed Therapy. Blood Cancer Discovery, 2021, 2, 326-337. | 5.0 | 71 |
| 6 | Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing. Cancer Discovery, 2021, 11, 3008-3027. | 9.4 | 88 |
| 7 | Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse. Nature Cancer, 2021, 2, 819-834. | 13.2 | 24 |
| 8 | St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem. Cancer Discovery, 2021, 11, 1082-1099. | 9.4 | 109 |
| 9 | The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. Nature Communications, 2021, 12, 6468. | 12.8 | 35 |
| 10 | The landscape of coding RNA editing events in pediatric cancer. BMC Cancer, 2021, 21, 1233. | 2.6 | 7 |
| 11 | Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. Nature Communications, 2020, 11, 5183. | 12.8 | 87 |
| 12 | Therapy-induced mutagenesis in relapsed ALL is supported by mutational signature analysis. Blood, 2020, 136, 2235-2237. | 1.4 | 1 |
| 13 | Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood, 2020, 135, 41-55. | 1.4 | 171 |
| 14 | The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment. Molecular Cancer Research, 2019, 17, 895-906. | 3.4 | 40 |
| 15 | Combating subclonal evolution of resistant cancer phenotypes. Nature Communications, 2017, 8, 1231. | 12.8 | 124 |
| 16 | Targeting Aberrant p70S6K Activation for Estrogen Receptorâ€“Negative Breast Cancer Prevention. Cancer Prevention Research, 2017, 10, 641-650. | 1.5 | 4 |
| 17 | HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Molecular Oncology, 2015, 9, 586-600. | 4.6 | 31 |
| 18 | PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. Cancer Biology and Therapy, 2015, 16, 402-411. | 3.4 | 44 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer. Cancer Research, 2015, 75, 4863-4875. | 0.9 | 44 |
| 20 | Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. Cell Research, 2014, 24, 542-559. | 12.0 | 23 |
| 21 | Enhanced PI3K p110Î± Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110Î±-Selective PI3K Inhibitor. Molecular Cancer Therapeutics, 2014, 13, 60-70. | 4.1 | 34 |
| 22 | Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer. Cancer Research, 2012, 72, 4417-4428. | 0.9 | 42 |
| 23 | Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nature Medicine, 2011, 17, 461-469. | 30.7 | 466 |